Active CD33 protein-coupled magnetic Beads

• Cat.No.: CD33-5833M

Specification

• Species: Human
• Appearance: Powder mixture
• Particle size: 2 μm
• Source: HEK293
• Protein length: Asp 18 - His 259
• Bio-activity: Immobilized 53.7 μg CD33 protein to 1 mg Beads, can bind the Anti-CD33 Antibody with an EC50 of 0.7794 μg/mL.
• Coupled amount of protein: ≈1827 pmol (53.7 μg) CD33/mg Beads
• Capacity: >267 pmol (40 μg) antibody/mg beads
• Formulation: PBS, pH7.4, with 10% Trehalose
• Reconstitution: 2 mL sterile deionized water (1 mg beads/mL)
• Background: The biotinylated CD33 protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-CD33 antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This CD33 coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.
• Application: This product is intended for immunocapture, biopanning and flow cytometry. This product is produced non-sterile.
• Storage: Upon receipt, please store the Beads at -20°C for 1 year in lyophilized state.

Reviews

11/14/2019

Quick dissolution, easy use.

08/27/2019

Excellent solubility, no aggregates.

02/27/2019

High concentration, very effective.

Q&As

What are the implications of CD33 polymorphisms in therapeutic targeting?

Certain polymorphisms in the CD33 gene can influence its expression on the cell surface, which might affect the efficacy of CD33-targeted therapies.

What is the primary biological function of CD33 in hematopoietic cells?

CD33 is a transmembrane receptor primarily expressed on cells of myeloid lineage and is involved in modulating cellular functions, including the regulation of cellular proliferation and differentiation.

How does CD33 expression vary among different leukocyte populations?

CD33 is predominantly expressed on myeloid cells, especially on immature myeloid cells. Its expression decreases as these cells differentiate and is typically low or absent on lymphoid cells.

How has CD33 been utilized as a therapeutic target in hematological malignancies?

CD33 has been targeted for therapeutic antibodies in AML. An example is gemtuzumab ozogamicin, which targets CD33 and delivers a cytotoxic agent specifically to leukemia cells expressing CD33.

How does CD33 signaling influence myeloid cell differentiation?

While the exact signaling pathways of CD33 are still under investigation, it is believed that CD33 signaling can influence the differentiation and function of myeloid cells, potentially playing a role in immune regulation.

What role does CD33 play in acute myeloid leukemia (AML)?

CD33 is commonly expressed on the surface of AML blasts, making it a potential target for therapeutic interventions in AML.

Are there known ligands that bind specifically to CD33?

The specific ligands for CD33 are not fully characterized, but it is believed to play a role in cell-cell interactions within the immune system.